| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011251963 |
| P356 | DOI | 10.1038/BMT.2016.81 |
| P698 | PubMed publication ID | 27042848 |
| P2093 | author name string | K Ohashi | |
| M Kapp | |||
| A Rovó | |||
| M Mohty | |||
| H Einsele | |||
| B N Savani | |||
| M Griffith | |||
| N S Majhail | |||
| A Tichelli | |||
| S Fuji | |||
| B G Engelhardt | |||
| P2860 | cites work | The impact of diabetes on the pathogenesis of sepsis | Q24616935 |
| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Cytokines in Graft-versus-Host Disease | Q28082195 | ||
| Adverse effects and safety of SGLT-2 inhibitors | Q28082331 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race | Q28363529 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| Intensive insulin therapy in critically ill patients | Q29618795 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Pharmacokinetics of high-dose oral and intravenous dexamethasone | Q73078603 | ||
| Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation | Q74535205 | ||
| Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation | Q77349323 | ||
| The incidence and impact of dextrose dose on hyperglycemia from parenteral nutrition (PN) exposure in hematopoietic stem cell transplant (HSCT) recipients | Q79801262 | ||
| Safe practices for parenteral nutrition | Q81068610 | ||
| Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation | Q81461343 | ||
| Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents | Q83389066 | ||
| Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation | Q84438843 | ||
| (7) Approaches to glycemic treatment | Q86396528 | ||
| Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies | Q87335557 | ||
| AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY | Q95462090 | ||
| Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy | Q46919825 | ||
| Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes | Q47103754 | ||
| Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study | Q50220965 | ||
| Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. | Q50733199 | ||
| Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. | Q51322506 | ||
| Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. | Q51351612 | ||
| The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. | Q51482187 | ||
| Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. | Q51553088 | ||
| Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation. | Q53429472 | ||
| Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. | Q53537221 | ||
| Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. | Q54096789 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry | Q33819684 | ||
| Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 | ||
| Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children | Q34148885 | ||
| Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation | Q34288406 | ||
| Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus | Q34419340 | ||
| Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery) | Q34507005 | ||
| Sliding scale insulin--time to stop sliding | Q34921052 | ||
| Vitamin D status among long-term survivors of hematopoietic cell transplantation. | Q35091259 | ||
| Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. | Q35203692 | ||
| Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. | Q35219625 | ||
| The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients | Q35235892 | ||
| Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases | Q35572174 | ||
| New-onset diabetes after renal transplantation: risk assessment and management | Q35620221 | ||
| Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation | Q35757247 | ||
| Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity | Q35849275 | ||
| Early basal insulin therapy decreases new-onset diabetes after renal transplantation. | Q35853273 | ||
| Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial | Q35973242 | ||
| The Effect of Changing Serum 25-Hydroxyvitamin D Concentrations on Metabolic Syndrome: A Longitudinal Analysis of Participants of a Preventive Health Program. | Q36102063 | ||
| Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease | Q36536621 | ||
| Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival | Q36662099 | ||
| Immunosuppressive drug-induced diabetes | Q36666296 | ||
| Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). | Q36715906 | ||
| Inpatient hyperglycemia: slide through the scale but cover the bases first | Q36740412 | ||
| What are the disadvantages of sliding-scale insulin? | Q36740420 | ||
| Therapy insight: the effect of tight glycemic control in acute illness | Q36742049 | ||
| Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose | Q36774508 | ||
| Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study). | Q36782816 | ||
| Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study | Q36807436 | ||
| Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation | Q36906212 | ||
| High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation | Q37066329 | ||
| Nutrition therapy recommendations for the management of adults with diabetes | Q37278232 | ||
| Glycemic variability: a strong independent predictor of mortality in critically ill patients | Q37282216 | ||
| Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation | Q37460433 | ||
| Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications | Q37512877 | ||
| Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? | Q37521395 | ||
| Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes | Q37598881 | ||
| Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis | Q37657964 | ||
| Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. | Q37885168 | ||
| Prevention and management of transplant-associated diabetes | Q37952000 | ||
| Complications associated with new-onset diabetes after kidney transplantation | Q37956123 | ||
| Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy | Q37977723 | ||
| Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes | Q37994337 | ||
| The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. | Q38099715 | ||
| Steroid-induced diabetes in rheumatologic patients | Q38154290 | ||
| Incretin based therapy in the management of steroid induced diabetes mellitus. | Q38260291 | ||
| Insulin tactics in type 2 diabetes. | Q38279793 | ||
| Benefits of timely basal insulin control in patients with type 2 diabetes. | Q38299208 | ||
| Hyperglycemia in patients with hematologic malignancies | Q38341651 | ||
| Treatment options for post-transplantation diabetes mellitus. | Q38390828 | ||
| Emerging treatments for post-transplantation diabetes mellitus | Q38445269 | ||
| Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy | Q38502148 | ||
| The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis | Q38537377 | ||
| Systematic Nutritional Support in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Q38546792 | ||
| Glycemic control in the critically ill: What have we learned since NICE-SUGAR? | Q38557229 | ||
| Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. | Q39049349 | ||
| The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: a pilot study | Q39694030 | ||
| Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. | Q39732493 | ||
| Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation | Q40897000 | ||
| Enhanced posttransplant management of patients with diabetes improves patient outcomes | Q42220901 | ||
| Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. | Q42576497 | ||
| Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum | Q42948845 | ||
| Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation | Q43297417 | ||
| Diabetes and the risk of infection-related mortality in the U.S. | Q43618995 | ||
| Early hyperglycemia after allogenic kidney transplantation | Q43933085 | ||
| Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. | Q44110185 | ||
| A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome | Q44235234 | ||
| Diabetes mellitus after kidney transplantation in the United States | Q44326129 | ||
| High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation | Q44976339 | ||
| Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study | Q46158158 | ||
| Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus | Q46208453 | ||
| Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. | Q46233510 | ||
| Management of diabetes and hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient | Q46296814 | ||
| Infection-related mortality is higher for kidney allograft recipients with pretransplant diabetes mellitus | Q46547500 | ||
| Early hyperglycemia after allogenic kidney transplantation: does it induce infections. | Q46698268 | ||
| Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation | Q46913129 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperglycemia | Q271993 |
| P304 | page(s) | 1041-1049 | |
| P577 | publication date | 2016-04-04 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. | |
| P478 | volume | 51 |
| Q39247468 | A review of infectious complications after haploidentical hematopoietic stem cell transplantations |
| Q47414810 | Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation |
| Q39035934 | Hyperglycemia as a possible risk factor for mold infections-the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation |
| Q61799686 | Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients |
| Q38717505 | Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities |
| Q46181268 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. |
| Q96304256 | Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach |
| Q100516140 | Optimization of nutrition support practices early after hematopoietic cell transplantation |
| Q46279340 | Psychosocial Response to New-Onset Diabetes as a Long-Term Effect of Allogeneic Hematopoietic Stem Cell Transplantation |
Search more.